Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data reveals how HAE drugs perform in chinese patients

NCT ID NCT06346899

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 115 Chinese people with hereditary angioedema (HAE) to see how well two approved drugs work in real life. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, treats sudden attacks. Researchers measured attack rates and how quickly symptoms resolved, while also tracking side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

115 people

The number who actually took part.

Started

Jul 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chinese participants who have received at least one dose of lanadelumab or icatibant from the lanadelumab national medical products administration (NMPA) approval date (02-Dec-2020) to the date of the day before the 1st site initiation date.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Chinese participants who have received at least one dose of lanadelumab or icatibant from the lanadelumab NMPA approval date (02-Dec-2020) to the date of the day before the 1st site initiation date. * Informed consent will be obtained from the participant (and/or a legally authorized representative) prior to including that participant as a study participant and accessing that participant's data, except for cases in which the informed consent can be waived by the site. Exclusion criteria: • Participation in other interventional studies involving lanadelumab, icatibant, or any other HAE drug or investigational product on or after the date of the participant's lanadelumab or icatibant initiation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary angioedema (HAE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary angioedema (HAE)

Contacts and locations

Locations

  • First Affiliated hospital of Kunming Medical University

    Kunming, Yunnan, 650032, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, 450003, China

  • Qianfo Mountain Hospital, Shandong Province

    Jinan, Shandong, 250014, China

  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200011, China

  • Shanxi Bethune hospital

    Taiyuan, Shanxi, 030032, China

  • The First Affiliated Hospital ,Sun Yat-sen University

    Guangzhou, Guangdong, 510080, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujan, 350005, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510260, China

  • The Second Affiliated hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310009, China

  • The Second Affiliated hospital of Xian Jiaotong University

    Xian, Shanxi, 710000, China

  • Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology

    Wuhan, Hubei, 430030, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.